MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Untargeted Serum Metabolomics Identifies Glycine-Serine Metabolism Disruption as Biochemical Bignature in Parkinson’s Disease

    A. Imarisio, C. Marino, M. Avenali, G. Buongarzone, M. Picascia, T. Nuzzo, C. Gasparri, F. Errico, M. Grimaldi, MC. Monti, A. Filosa, M. Rondanelli, C. Pacchetti, AM. D'Ursi, A. Usiello, EM. Valente (Pavia, Italy)

    Objective: We attempted to identify a metabolomic signature distinctive of Parkinson’s disease (PD) through an untargeted metabolomics approach. Background: Using an high-performance liquid chromatography targeted…
  • 2024 International Congress

    Distinct Gut Microbiome in Parkinson’s disease Based on the Presence of Premotor Rapid-Eye Movement Sleep Behavior Disorders: Exploring the Alpha-synuclein

    S. Jo, J-Y. Lee, J. Lee, J-W. Bae, SJ. Chung (Seoul, Republic of Korea)

    Objective: We aim to investigate the microbiome composition and functional profiles in Parkinson’s disease (PD) patients with and without premotor rapid eye movement sleep behavior…
  • 2024 International Congress

    Age and Parkinson’s disease: clinical and biomarkers profiling of younger and older patients

    G. Di Lazzaro, F. Paolini Paoletti, G. Bellomo, T. Schirinzi, P. Grillo, G. Giuffrè, A. Picca, M. Petracca, AR. Bentivoglio, NB. Mercuri, L. Parnetti, P. Calabresi (Rome, Italy)

    Objective: Given the well-known clinical differences and natural history of Parkinson's disease (PD) according ot patients age, wthis study aims at exploring the different pathophysiological…
  • 2024 International Congress

    Cross-Omics Clustering Identifies Common Molecular Patterns in Parkinson’s Disease

    M. Lai, B. Benitez (Boston, USA)

    Objective: Uncover novel molecular signatures to define Parkinson's disease (PD) patients' clusters using multi-omics integration and evaluate clinical and neuroimaging data. Background: PD is a…
  • 2024 International Congress

    Functionality Analysis of Immunoregulatory Cells Stimulated with Dopaminergic Agonists in People Living with Parkinson’s Disease

    AY. Regalado-Mustafá, DD. álvarez-Luquín, A. Guevara-Salinas, MA. Bravo-Martinez, EJ. Gallegos-Altamirano, CF. álvarez-Hernández, E. Ichikawa-Escamilla, AM. Peralta-Maza, V. Morales-Ruiz, EE. Sevilla-Reyes, JI. Velasco-Velázquez, JE. Estudillo-Hernández, M. Rodríguez-Violante, LV. Adalid-Peralta (Mexico City, Mexico)

    Objective: To evaluate the effect of dopaminergic agonists (DA) on the activation and functionality of regulatory cells in People living with Parkinson's Disease (PwP). Background:…
  • 2024 International Congress

    LRRK2 I1371V Mutation: Unraveling Pathogenic Mechanisms in Dopaminergic Neurons via Membrane Fluidity & Calcium Dysregulation using PD Patient iPSCs

    I. Datta, S. Jagtap, V. Holla, N. Kamble, R. Yadav, P. Pal (Bengaluru, India)

    Objective: To estimate pathogenicity of LRRK2 I1371V mutation in PD patient iPSC-derived DA-neurons & assess underlying disease mechanisms involving membrane fluidity, Ca2+ dysregulation, & Rab8A/Rab10…
  • 2024 International Congress

    Identification of Pre-Diagnostic Biomarkers for Parkinson’s Disease from Plasma Proteome

    M. Ta, E. Appleton, S. Khosousi, A. Sturchio, I. Markaki, W. Paslawski, C. Blauwendraat, M. Nalls, A. Singleton, P. Svenningsson, H. Iwaki (Bethesda, USA)

    Objective: To identify pre-diagnostic biomarkers for Parkinson’s Disease (PD) from the plasma proteome. Background: The plasma proteome is a non-invasive and accessible measure to assess…
  • 2024 International Congress

    The role of LRRK2 in regulating microglial activity in Parkinson’s disease

    S. Brooker, A. Thomas, D. Krainc (Chicago, USA)

    Objective: To investigate the effects of pathogenic LRRK2 mutations on lysosomal function and phagocytic activity of microglia. Background: The LRRK2 G2019S mutation is one of…
  • 2024 International Congress

    Studying digenic Parkinson’s disease in a stem cell model carrying mutant p.N409S in the GBA1 gene and the homozygous deletion of exon 3 PARK2

    C. Oleksy, Z. Hanss, F. Massart, G. Arena, I. Boussaad, R. Krüger (Belvaux, Luxembourg)

    Objective: We aim to study the combined effect of the GBA1 p.N409S mutation and a complete loss of Parkin based on a patient-based stem cell…
  • 2024 International Congress

    Baseline Variables Associated with Apomorphine Sublingual Film Retention

    J. Kassubek, J. Schwarz, L. López Manzanares, M. Fonseca, C. Denecke Muhr (Ulm, Germany)

    Objective: The aim of this analysis was to identify the baseline variables that differ between patients who completed Study CTH-301 and those who discontinued during…
  • « Previous Page
  • 1
  • …
  • 424
  • 425
  • 426
  • 427
  • 428
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley